First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.

doi:10.1080/15384047.2024.2441499

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.

Cancer biology & therapy - 1 Dec 2025

He Qi, Liu Xiaoyan, Jiang Liyan, Liu Ping, Xuan Weixia, Wang Yudong, Meng Rui, Feng Huijing, Lv Shuang, Miao Qian, Zheng Di, Xu Yan, Wang Mengzhao

Abstract excerpt

KRAS mutations are common in non-small cell lung cancer (NSCLC) and are associated with patient prognosis; however, targeting KRAS has faced various difficulties. Currently, immunotherapy, chemotherapy, and chemoimmunotherapy play pivotal roles in the first-line treatment of KRAS-mutated NSCLC. Here, we summarize the current evidence on first-line therapies and compare the treatment outcomes and biomarkers for...

Topics

Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Proto-Oncogene Proteins p21(ras)
Mutation
Immunotherapy
Molecular Targeted Therapy

Source

Open in PubMed

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Open full text

Identifiers

PMID: 39681355
DOI: 10.1080/15384047.2024.2441499
PMCID: PMC11651285

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.